Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients
- 542 Downloads
Information on complementary and alternative medicine (CAM) use in Australian radiotherapy patients is sparse. This study investigated the type and prevalence of CAM amongst an Australian regional radiotherapy patient cohort and the disclosure of information to the consultant radiation oncologist.
A single hardcopy questionnaire survey was provided to patients regarding the use of CAM and discussion with the treating medical practitioner. The National Centre for Complementary and Alternative Medicine (NCCAM) classification was used to group responses. The study was open for a period of 4 months, and all patients on treatment during this period were approached.
A total of 170 questionnaires were distributed to eligible patients, and 152 patients returned a completed questionnaire (89.4 % response rate). Sixty-nine of the 152 patients (45.4 %) reported active CAM use. Of the 69 patients who used CAM, mind–body medicine (n = 54, 78.3 %) and biological-based therapies (n = 54, 78.3 %) were the commonest NCCAM group, whilst manipulative/body-based therapies (n = 44, 63.8 %), whole medical systems (n = 7, 10.1 %) and energy therapies (n = 5, 7.2 %) were the least common. The most common therapies were vitamins and mineral supplementation (n = 33, 47.8 %) and massage therapy (n = 18, 26.1 %). Of note, only 29 participants stated that they had discussed CAM therapies with their radiation oncologist.
CAM use was prevalent amongst cancer patients undergoing radiotherapy, but frequently not discussed with the treating radiation oncologist. Considering the high prevalence of CAM, further resources could be justifiably directed at providing this service for cancer patients to foster a more holistic approach to their care.
KeywordsAlternative medicine Australia Complementary therapies Radiation oncology Radiotherapy
The authors wish to acknowledge the input and assistance of Judy Andrews, Catherine Anderson and Kathleen Murphy. In addition, the authors would like to thank the patients who participated in this study.
Conflict of interest statement
There is no conflict of interest to note.
- 1.National Institute of Health, National Centre for Complementary and Alternative Medicine. What is Complementary and Alternative Medicine. Available from:-http://nccam.nih.gov/health/whatiscam; Accessed 26th October 2013
- 5.Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol Off J Am Soc Clin Oncol 18(13):2505–2514Google Scholar
- 12.Field KM, Jenkins MA, Friedlander ML, McKinley JM, Price MA, Weideman P, Keogh LA, McLachlan SA, Lindeman GJ, Hopper JL, Butow PN, Phillips KA (2009) Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer. Eur J Cancer 45(4):551–560. doi: 10.1016/j.ejca.2008.09.023 PubMedCrossRefGoogle Scholar
- 13.Pedersen CG, Christensen S, Jensen AB, Zachariae R (2009) Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45(18):3172–3181. doi: 10.1016/j.ejca.2009.09.005 PubMedCrossRefGoogle Scholar
- 14.Kao GD, Devine P (2000) Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88(3):615–619. doi: 10.1002/(SICI)1097-0142(20000201)88:3<615::AID-CNCR18>3.0.CO;2-P PubMedCrossRefGoogle Scholar
- 20.Baum M, Ernst E, Lejeune S, Horneber M (2006) Role of complementary and alternative medicine in the care of patients with breast cancer: report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004. Eur J Cancer 42(12):1702–1710. doi: 10.1016/j.ejca.2006.02.020 PubMedCrossRefGoogle Scholar
- 21.Pirri C (2011) Integrating complementary and conventional medicine. Cancer Forum 35(1):1–9Google Scholar
- 23.Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, and Collins SP (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 8: p. 58. DOI: 10.1186/1748-717X-8-58